Inhaled pain drug Penthrox approved for marketing in France

Mundipharma International today announced that Penthrox(low dose methoxyflurane) has been granted marketing authorization in France for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

Penthrox is manufactured by the Australian company Medical Developments International, which received the French marketing authorization. Mundipharma has the exclusive product rights in 39 European markets including France, Belgium, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the UK.

“Mundipharma has a proud heritage in pain management and is committed to advancing important new therapeutics in this space,” commented Kate Hurtig, head of pain at Mundipharma International, adding: “Penthrox is our first analgesic for use in the emergency care setting. It offers the potential to manage emergency pain in a completely different way to existing treatment options and we are excited about the prospect for growth which that brings.”